>[ddd]^DRAMP18014^^ILRWPWWPWRRK^^MBI-226^^Synthetic cationic peptide derived from indolicidin^^Antibacterial, Antifungal^^Topical antiseptic, prevention of central venous catheter-related bloodstream infections; antiinﬂammatory for acne
vulgaris and papulopustular rosacea. (ClinicalTrials.gov Identifier: NCT00211523 and NCT00211497 and NCT00027248).^^Phase II & III (Completed)^^Missed primary end point (infections) but achieved secondary end points of microbiologically confirmed infections and catheter colonization. MBI 226 has failed to achieve New Drug Application (NDA) approval, usually not because of lack of activity but rather an inability to demonstrate an advantage over existing therapeutics (i.e. non-equivalence).^^BioWest Therapeutics Inc.^^Clinical bacterial isolates (CA MH broth; UA MH broth): Oxacillin-susceptible CoNS (MIC=0.5-8; 0.5-4 µg/ml), Oxacillin-resistant CoNS (MIC=0.5-16; ≤0.25-4 µg/ml), Oxacillin-susceptible S. aureus (MIC=2-32; 1-32 µg/ml). Oxacillin-resistant S. aureus (MIC=8-64; 4-64 µg/ml), Vancomycin-susceptible E. faecalis (MIC=16-128; 16-128 µg/ml), Vancomycin-nonsusceptible E. faecalis (MIC=64-128; 32-64 µg/ml), Vancomycin-susceptible E. faecium (MIC=2-16; 2-16 µg/ml), Vancomycin-nonsusceptible E. faecium (MIC=2-16; 2-16 µg/ml), Beta-hemolytic streptococci (MIC=2-128; 1-64 µg/ml), Penicillin-susceptible viridans group streptococci (MIC=4-512; 1-512 µg/ml), Penicillin-nonsusceptible viridans group streptococci (MIC=4-256; 2-256 µg/ml), Bacillus spp. (MIC≤0.25-64; ≤0.25-64 µg/ml), Corynebacterium spp. (MIC≤0.25-64; ≤0.25-32 µg/ml), Enterobacter spp. (MIC=8 - >512; 4-512 µg/ml); E. coli (MIC=8-64; 4-32 µg/ml), Klebsiella spp. (MIC=8-512; 4-512 µg/ml), P. aeruginosa (MIC=16-256; 16-256 µg/ml).##Clinical yeast isolates: C. albicans (MIC=32 - >512), C. glabrata (MIC=128-512 µg/ml), C. krusei (MIC=16-256 µg/ml), C. parapsilosis (MIC=32-256 µg/ml), C. tropicalis (MIC=8-64 µg/ml). ^^Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity. (PMID: 15273128)##MBI-226. Micrologix/Fujisawa. (PMID: 14508884)^[ddd]
2 cationic peptide derived from indolicidin^^Antibacterial, Antifungal^^Topical antiseptic, prevention of central venous catheter-related bloodstream infections
